7 recent drug approvals

Seven FDA drug, treatment approvals since mid-June:

  1. Keytruda — Merck's Keytruda has been approved to treat triple-negative breast cancer in combination with chemotherapy. The drug has now been approved to treat 30 types of cancer.

  2. Bydureon — AstraZeneca's Bydureon has been approved to treat Type 2 diabetes in pediatric patients ages 10 years and older. 

  1. Rezurock — Kadmon Pharmaceuticals' Rezurock has been approved to treat chronic graft-versus-host disease.

  2. Wegovy  — Novo Nordisk's Wegovy has been approved to treat obesity, the first new drug to treat the condition approved by the FDA in seven years.

  3. Rylaze — Jazz Pharmaceuticals' Rylaze has been approved as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the drugs used most commonly for treatment.

  4. Pradaxa — Boehringer Ingelheim's Pradaxa has been approved to treat venous thromboembolism, a condition where blood clots form in the veins, in children 3 months to under 12 years old. It is the first FDA-approved blood-thinning medication that children can take by mouth.

  5. Astepro  — Bayer's Astepro, a nasal antihistamine, has been approved for nonprescription use. Astepro is approved to treat seasonal and perennial allergic rhinitis in adults and children over 6 years.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars